Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03517449 · ClinicalTrials.gov registry record · Phase 3
Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])
A Phase 3 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 3
- Development phase
- 827
- Enrollment target
NCT03517449 is a Phase 3 study that has completed, run by Eisai. The registered enrollment target is 827 participants.
The verdict
NCT03517449, a Phase 3 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 827 participants
- Enrollment target
Study Summary
This is a study of pembrolizumab (MK-3475, KEYTRUDA®) in combination with lenvatinib (E7080) versus treatment of physician's choice (doxorubicin or paclitaxel) for the treatment of advanced endometrial cancer. Participants will be randomly assigned to receive either pembrolizumab and lenvatinib or treatment of physician's choice. The primary study hypothesis is that pembrolizumab in combination with lenvatinib prolongs progression free survival (PFS) and overall survival (OS) when compared to treatment of physician's choice.
Interventions
- DRUG Pembrolizumab
- DRUG Doxorubicin
- DRUG Paclitaxel
- DRUG Lenvatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 827 participants |
| Start Date | 2018-06-11 |
| Est. Completion | 2025-02-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03517449
The ClinicalTrials.gov registry entry for NCT03517449 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 827 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT03517449 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03517449 about?
NCT03517449 is a clinical study titled "Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])". This is a study of pembrolizumab (MK-3475, KEYTRUDA®) in combination with lenvatinib (E7080) versus treatment of physician's choice (doxorubicin or paclitaxel) for the treatment of advanced endometrial cancer. Participants will be randomly assigned to receive either pembrolizumab and lenvatinib or t...
What is the current status of trial NCT03517449?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 827 participants. The study started on 2018-06-11. Estimated completion is 2025-02-26.
What interventions are being tested in trial NCT03517449?
The interventions under investigation include: Pembrolizumab (DRUG), Doxorubicin (DRUG), Paclitaxel (DRUG), Lenvatinib (DRUG).
Who is sponsoring clinical trial NCT03517449?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.